Cardiovascular outcomes of empagliflozin-GLP-1RA combination therapy in type 2 diabetes: EMPRISE study.
Combining two diabetes medications protects the heart better than either one alone, offering people real cardiovascular benefits alongside their blood sugar control.
This EMPRISE cohort study emulating two comparative effectiveness trials in US healthcare databases demonstrates that combining empagliflozin with GLP-1RA therapy in type 2 diabetes patients provides substantially greater cardiovascular protection than either single-agent add-on comparator, adjusting for 130+ baseline covariates via propensity score matching. The findings directly support additive cardiovascular benefits of dual SGLT2i+GLP-1RA therapy with clinically meaningful reductions in MACE and heart failure hospitalizations across diverse US patient populations.
What the study was
- Study design
- emulated trial cohort (real-world databases)
- Population
- Type 2 diabetes patients in US healthcare databases (Medicare, Optum Clinformatics, MarketScan, 2013-2022)
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Cardiovasc Diabetol
Why it surfaced
Landmark real-world EMPRISE study of SGLT2i+GLP-1RA combination; largest real-world evidence base for this combination in T2D from three US databases; propensity-matched trial emulation; directly actionable for cardiometabolic prescribing decisions; published in Cardiovascular Diabetology.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.